The Other Side of Possible...

What does OSOP mean to us?

Unwavering Commitment
to Science and Patients

Learn About
Our Research Platform

Everett Thomas Cavan was the first child born to parents Jim and Deana on April 27, 2014. As this little boy with huge celestial blue eyes grew they wondered what life would have in store for him—he seemed remarkable in some way. Certainly all parents feel that way about each of their children, but little Rett knew something his parents didn’t—his life on this earth would be short and powerful...

What Drives Us?

The many friends and family of Agios employees affected by cancer are what motives inspires and drives us.

"I joined Agios because when people here said there was “freedom to do great science at Agios” they were being honest and not just talking on message. When I joined, it felt liberating to be enabled to attack real questions with real impact. That feeling is what gets me up everyday to come in....that I am being empowered for success and that that success is tangible for people beyond our building."
- Brandon

Our Research Focus

Cancer Metabolism

Inhibit key enzymes in cancer cell specific metabolic pathways to disrupt tumor cell proliferation and survival

Rare Genetic Diseases

Restore defective metabolic pathways in disease cells that cause rare genetic disorders of metabolism

Metabolic
Immuno-Oncology

Alter the metabolic state of immune cells to enhance the body’s anti-tumor response

Boldly Pursuing Excellence and Innovation

We are a research-driven organization focused on creating transformative medicines by combining expertise in metabolism and precision medicine.

research platform
The Spirit of Agios

The Spirit of Agios

At Agios, our culture and values are embodied in the Greek word Arete, the ancient ideal of excellence and fulfillment of one's potential to which our employees aspire. Together, we are driven by a boundless passion for our work, and we pride ourselves on fostering an interconnected environment that encourages creative scientific collaboration across disciplines.

explore agios' culture

Passion for Discovery

our pipeline

Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases.

CANDIDATE
Early Stage Clinical Development
Late Stage Development
FILED
R/R AML
Phase 3
R/R AML
Phase 1/2
Frontline AML
Phase 1b 7+3 Combo
Frontline AML
Phase 1/2 VIDAZA® Combo
  • Celgene has worldwide development and commercialization rights.

    Agios has U.S. co –promotion and royalty rights.

  • Enasidenib
Frontline AML
Phase 3 (1H' 17)
R/R AML
Phase 1 Dose Escalation
Expansion Cohorts
Frontline AML
Phase 1b 7+3 Combo
Frontline AML
Phase 1/2 VIDAZA® Combo
Solid Tumors
Phase 1 Dose Escalation
Expansion Cohorts
Cholangiocarcinoma
Phase 3
Solid Tumors
Phase 1 Dose Escalation
  • Joint worldwide collaboration with Celgene.

  • AG-881

The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Recent News & Events

05/18/2017

Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHA
read more

05/17/2017

Agios to Present New Clinical Data from its IDH Programs at ASCO
read more

05/04/2017

Agios Reports First Quarter 2017 Financial Results
read more

04/28/2017

Agios Announces Closing of Over-Allotment Option in Public Offering
read more

Agios has a dynamic culture that supports our employees’ unwavering commitment to science and patients.

career opportunities